Agents are being developed for treatment of eosinophilic esophagitis (EoE). However, it is not clear what outcome measures would best determine the efficacy and safety of these agents in clinical trials. We performed a systematic review of outcomes used in randomized placebocontrolled trials of EoE and we estimate the placebo response and rates of remission.
appearance. The median histologic response to placebo was 3.7% (range, 0%-31.6%) and the median rate of remission in patients given placebo was 0.0% (range, 0%-11.0%). The median patient-reported response to placebo was 14.4% (range, 8.6%-77.8%) and rate of remission in patients given placebo was 26.2% (range, 13.2%-35.7%).
CONCLUSIONS:
In a systematic review of the literature, we found that no standardized definitions of histologic, endoscopic, or patient-reported outcomes are used to determine whether pharmacologic agents produce a response or remission in patients with EoE. A core outcome set is needed to reduce heterogeneity in outcome reporting and facilitate trial interpretation and comparison of results from trials.
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E osinophilic esophagitis (EoE) is a chronic inflammatory condition characterized histologically by eosinophilic infiltration and clinically by symptoms of esophageal dysfunction in the context of an antigenmediated immune response. 1 Consensus guidelines have established first-line pharmacologic, dietary, and endoscopic treatment for EoE, emphasizing the role of topical corticosteroids, dietary restriction, and endoscopic dilation targeted at improving patient symptoms and reducing histologic eosinophil burden. 2, 3 Topical corticosteroids are the mainstay of drug-based therapy, but there are no US Food and Drug Administration (FDA)-approved treatments, and only 1 orodispersible budesonide formulation has been approved by the European Medicines Agency for treatment of EoE. 4, 5 Accordingly, there is great interest in therapeutic development in this field, with multiple classes of agents under evaluation.
Several barriers to efficient drug development in EoE exist. 6 Importantly, there is a lack of standardized outcome measures for use in registration trials that can support labelling claims. The FDA mandates that "clinically meaningful" endpoints that measure the way patients feel, function, and survive be used. 7 Therefore, analogous to randomized controlled trials (RCTs) in inflammatory bowel disease (IBD), future EoE clinical trials are likely to incorporate co-primary endpoints featuring both patient-reported outcomes (PROs) and objective inflammatory measures. Nevertheless, there is uncertainty regarding the appropriateness of endpoint definitions and the responsiveness of current disease activity indices in EoE, 8 and unsurprisingly, there is lack of consensus on the type of outcomes to measure, the way these outcomes should be defined, and the circumstances in which these outcomes should be assessed. 9 Developing a core outcome set (COS) is thus a priority in EoE research. A COS is a consensus-derived minimum set of outcomes that should be measured and reported in all clinical trials in a given field. 10 Adoption of a COS minimizes heterogeneity in reporting and potential publication bias, improves the quality of evidence synthesis, and facilitates comparisons of interventions in meta-analyses. COS development is a multi-step process that involves systematically reviewing the literature to identify current trial endpoints, surveying affected stakeholders, and achieving consensus. 10 A similar COS development initiative is underway in IBD. 11, 12 In addition to selecting appropriate endpoints, understanding the placebo response in clinical trials is critical for efficient drug development. Furthermore, this process facilitates accurate sample size calculations and maximizes assay sensitivity for detecting true differences between active comparator and placebo. Although placebo rates in other gastrointestinal disorders have been well-characterized, [13] [14] [15] placebo rates and the determinants of the placebo response in EoE RCTs require further evaluation. Hirano et al 16 have previously demonstrated in a phase 2 trial of budesonide oral suspension that despite a placebo run-in period, symptom improvement occurred in approximately one-fourth of patients randomized to placebo, with no baseline demographic features predictive of this response.
To address these limitations, we systematically reviewed all randomized, placebo-controlled trials of pharmacologic interventions in EoE. We aim to describe placebo rates in EoE trials, identify relevant endpoints and outcome definitions used in current EoE trials, and establish a conceptual framework by which a COS for future EoE trials can be developed.
Methods

Search Strategy
MEDLINE (Ovid, 1948 (Ovid, -2017 , Embase (Ovid, 1947 (Ovid, -2017 , and CENTRAL (1994-2017) were searched without language restriction from inception to February 20, 2018 for RCTs of pharmacologic interventions in EoE. Using the PICO framework, we aimed to capture all studies enrolling patients with EoE regardless of age (patient population), undergoing pharmacologic therapy (intervention), compared against placebo (comparator), and describing any symptom-based, endoscopic, histologic, or exploratory outcomes (outcome). The search strategy is outlined in Supplementary File 1. Conference proceedings from Digestive Disease Week and United European Gastroenterology Week (2012-2017) and references of relevant studies and review articles were hand-searched to identify additional studies. Finally, ClinicalTrials.gov and the European Union Clinical Trials Register were searched for registered, actively recruiting RCTs. Citations and abstracts were screened, and complete manuscripts were retrieved for potentially eligible studies. Articles were independently assessed by 2 investigators (T.M.N., B.vR.), and disagreement was resolved by consensus and discussion with a third reviewer (C.M.). All data were extracted independently, and accuracy was verified in a quality control process by a third investigator (C.E.P.).
Study Eligibility Criteria
Studies were eligible for inclusion if they reported a randomized, placebo-controlled trial in patients with EoE that evaluated a pharmacologic intervention. Similar criteria were applied to registered trials on ClinicalTrials. gov and the European Union Clinical Trials Register. Studies of children, adolescents, or adults were eligible. However, trials of endoscopic dilation or dietary exclusion therapies and trials without a placebo comparator arm were excluded. These restrictions were applied to focus this review on pharmacologic interventions, although we recognize that similar challenges with respect to minimizing placebo response and outcome heterogeneity apply to trials of dietary or endoscopic therapy and non-placebo-controlled studies. Separately published post hoc or retrospective analyses of RCTs were not included to avoid duplicate inclusion.
Data Extraction
The primary data extraction included (1) descriptions of primary and secondary efficacy outcomes, definitions, and measurement tools; (2) descriptions of exploratory outcomes; and (3) the proportion of patients randomized to placebo achieving patient-reported, endoscopic, or histologic response and remission (as defined by the original study authors). In addition, information regarding trial design (publication year, trial phase, number of treatment arms, trial location and number of trial centers, total participants and participants randomized to placebo, follow-up duration), trial-level patient data (age and gender distribution, proportion on proton pump inhibitor [PPI] therapy at baseline, disease duration), and the active comparator (drug class and route of administration) were collected.
The risk of bias in the published studies was assessed by using the Cochrane risk of bias tool, which assesses the following domains: (1) selection bias (random sequence generation, allocation concealment); (2) performance bias (blinding of participants and personnel); (3) detection bias (blinding of outcome assessment); (4) attrition bias (incomplete outcome data); (5) reporting bias (selective reporting); and (6) other sources of bias. 17 
Data Synthesis and Analysis
Standard descriptive statistics were used to describe trial characteristics. A comprehensive inventory of outcomes and definitions was generated through qualitative review and subsequently organized into subdomains (histology, endoscopy, PROs). The proportion of studies reporting each outcome was calculated and stratified by year of publication.
In the initial study protocol, we planned to pool histologic, endoscopic, and patient-reported placebo response and remission rates in meta-analysis by using a random-effects model; however, because of the small number of trials and significant heterogeneity in outcome definitions, it was methodologically inappropriate to formally pool reported placebo rates. In addition, a substantial proportion of trials reported placebo rates of 0%; pooling these studies in meta-analysis, even with a continuity factor, would likely result in biased estimates. Therefore, we generated a descriptive summary of the proportion of placebo responders or remitters where available but without pooled point estimates. For studies reporting quantitative before and after treatment changes in the mean or median scoring index, the percentage change in the placebo group was calculated by dividing the difference in quantitative score after treatment by the scale of the scoring instrument. The median and interquartile range of placebo response and remission rates were calculated and then graphically depicted in box-and-whisker, stratified by outcome domain. All statistical analyses were conducted by using STATA 14.2 (StataCorp, College Station, TX; StataCorp LP).
This meta-analysis conforms to the Preferred Reporting Items for Systematic Reviews and MetaAnalyses (PRISMA) recommendations. 18 
Results
Search Results and Study Characteristics
The flow diagram for inclusion of trials identified by the literature search is illustrated in Supplementary  Figure 1 . Twenty-two placebo-controlled RCTs were identified; another 10 registered and enrolling trials were identified through ClinicalTrials.gov and the European Union Clinical Trials Register. Baseline study characteristics are summarized in 
Outcome Reporting
The proportion of trials reporting histologic, endoscopic, and PROs is summarized in Figure 1 , stratified by year of publication. Both histologic and patient-reported outcomes were described in nearly all reported trials (95.5%, 21/22) and registered studies (90%, 9/10). In contrast, only 13 21, 27 cytokeratin, 21, 23 terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate nickend labeling positive inflammatory and epithelial cells, 21, 23 transforming growth factor beta (TGFb), [20] [21] [22] [23] 25, 27 CD3/8, 
Histology Outcome Definitions
Definitions of histology outcomes for reported RCTs are summarized in Table 2 and for registered RCTs in Table 3 . Most trials defined histology outcomes by using eosinophil density as defined most commonly by peak eosinophil counts, although no consistent thresholds for defining histologic response or remission were used. Furthermore, the definition of peak eosinophil count varied depending on field size, number of high-power fields (HPFs) evaluated, and from which level of the esophagus samples were obtained. For histologic remission, peak eosinophil thresholds ranged from 0 to 6 PPI, proton pump inhibitor; SD, standard deviation. 
Endoscopy Outcome Definitions
Definitions of endoscopy outcomes for reported RCTs are summarized in Table 2 and for registered RCTs in Table 3 . Several authors used non-validated changes in overall or global endoscopic appearance with descriptions of classic EoE endoscopy findings (such as linear furrows, white exudates, and esophageal rings). Two studies used a visual analogue scale, 27, 33 and 4 studies used the EoE Endoscopic Reference Score (EREFS). 32, [36] [37] [38] The EREFS is the only endoscopic outcome instrument that has undergone interobserver and intraobserver validation in both North American and European studies. The EREFS is also the most commonly used measurement tool for endoscopy outcomes in registered trials (4 studies, 40%). No consistently used thresholds for endoscopy scores were identified to determine endoscopic response/remission; rather, changes compared with baseline were commonly reported.
Patient-Reported Outcome Definitions
Definitions of PROs for reported RCTs are summarized in Table 2 and for registered RCTs in Table 3 . Multiple different scoring systems, mostly non-validated or only partially validated, have been used to assess patient-reported response or remission. These include the Mayo Dysphagia Questionnaire, 24, 30, 34 the Dysphagia Symptom Questionnaire, 36 the EoE Activity Index (EEsAI), 40 patient or physician global assessments of disease severity, 26, 32, 37, 40 the Dysphagia Score (also termed the Straumann Dysphagia Index), [21] [22] [23] the EoE Clinical Symptom Score, 28, 31 the Pediatric Eosinophilic Esophagitis Symptom Score, 20 and the Visual Dysphagia Questionnaire. 27 As with endoscopy and histology endpoints, no uniformly applied thresholds for patientreported remission or response have been identified, although the complete absence of symptoms has been used by some authors to define remission. Health-related quality of life was not specifically defined as a treatment endpoint in any of the currently published RCTs. 
Histology, Endoscopy, and Patient-Reported Placebo Rates
Placebo rates in EoE RCTs are summarized in Figure 2 and Table 4 , presented as either (1) proportion of patients achieving response/remission defined by the original study authors or (2) percentage change in before and after treatment disease activity scores relative to the scale of scoring index when placebo response was reported as a continuous variable. The median histologic placebo response rate was 3.7% (range, 0%-31.6%). Two studies reported histologic placebo response or partial remission rates of >20%. Both studies used an eosinophil density cutoff of <20 eosinophils/HPF (<65 eosinophils/mm 2 HPF). 23, 33 The median histologic placebo remission rate was 0.0% (range, 0%-11.0%). Eight studies reported histologic placebo remission rates of 0%. 20, 21, 23, 24, 28, 33, 39, 40 When assessed as a continuous measure relative to the scale of the measurement tool, endoscopy scores before and after placebo administration changed between -0.6% to -16%. Larger variances were evident when assessing patient-reported placebo response ( Figure 2) ; patient-reported scores before and after placebo administration varied between -28.6% to þ36.6%. The median symptomatic response rate was 14.4% (range, 8.6%-77.8%); the median symptomatic remission rate was 26.2% (range, 13.2%-35.7%).
Discussion
During the past 2 decades, clinical trials of therapeutic agents in EoE have evolved from retrospective case series with symptom-based outcomes to prospective, randomized, placebo-controlled trials that include both valid PROs and objective measures such as histopathology and endoscopy. In this systematic review of all reported and registered placebo-controlled trials of pharmacologic therapies for EoE, we describe the placebo response and summarize the outcome measures used in existing and planned RCTs. We found that histologic placebo response and remission rates in EoE trials are relatively low compared with RCTs in other gastrointestinal disorders, although there is greater variance in patient-reported placebo responses. We also highlight the significant heterogeneity in outcome measurement and outcome definitions used in current studies for histology, endoscopy, and patient-reported endpoints, and there is no consensus on thresholds for defining response or remission. 9 Development of a COS that standardizes outcome measurement and reporting in EoE RCTs is thus a priority.
Potential determinants of the histologic placebo response in EoE RCTs include (1) inclusion of patients with PPI-responsive EoE who derive both clinical and histologic benefits from concomitant PPI therapy 41 ; (2) sampling of histologically normal mucosa in the context of patchy eosinophilic infiltration in EoE; (3) regression to the mean; and (4) spontaneous changes in disease activity in the natural history of EoE, possibly as a response to fluctuations in allergen or dietary exposures. Although symptomatic placebo rates in EoE tend to be lower than in other allergic and gastrointestinal disorders, 42, 43 they still remain higher and more variable compared with histologic placebo response. Some EoE studies report greater than one-third to one-half of Figure 2 . Box-and-whisker plots for histologic, endoscopic, and symptombased placebo response and remission in EoE clinical trials. placebo patients achieving response or remission using patient-reported endpoints. 23, 31, 36 Symptomatic placebo rates may be influenced by dietary avoidance or modifications that reduce dysphagia or by endoscopic dilation at baseline if not precluded by the study entry criteria. However, this discrepancy between histologic and symptomatic placebo response also underscores the discordance between patient-reported symptoms and objective measures of disease activity; in an international cohort study of 269 EoE patients, an EEsAI PRO score of 15 points identified only 67.2% of patients with endoscopic and histologic remission. 44 In addition, histologic endpoints defined by eosinophil density may not closely correlate with PROs because dysphagia symptoms and risk of food impaction in EoE are driven primarily by complications of esophageal remodeling rather than mucosal inflammation. 45, 46 Histologic outcomes are assessed in nearly all EoE RCTs defined by either peak or mean eosinophil count per HPF. Although this paradigm is attractive because it provides a quantitative measure of inflammatory burden, several potential pitfalls exist. First, variability in results may be influenced by technical factors such as the crosssectional area of the microscope manufacturer (correctable by using normalized density to eosinophils per mm 2 ) and by sampling differences in the number and location of acquired biopsies. [47] [48] [49] Second, mucosal biopsies may underestimate the full extent of histologic involvement in EoE because eosinophilic infiltration is not confined to the superficial mucosa, eosinophil density does not necessarily correlate with eosinophil degranulation or function, and other histologic features such as basal cell hyperplasia, mast cell infiltration, and subepithelial fibrosis are not captured. 50, 51 To address some of these potential limitations of peak eosinophil density as a measure of disease activity in EoE, Collins et al 52 have developed and validated an EoE-HSS, which is based on 8 features (eosinophil density, basal zone hyperplasia, eosinophil abscesses, eosinophil surface layering, dilated intercellular spaces, surface epithelial alteration, dyskeratotic epithelial cells, and lamina propria fibrosis), graded and staged by using a 4-point scale. Future studies should assess the responsiveness to change of this instrument after a therapeutic intervention. Furthermore, adoption of blinded central reading to minimize observation bias at both enrollment and outcome ascertainment has gained traction in IBD. Although a single pathologist frequently evaluates histologic endpoints in current EoE RCTs, proper assessment of inter-rater and intra-rater reliability by using multiple blinded central readers for EoE histopathology endpoints is needed before this is routinely incorporated in clinical trials.
Patient-reported outcomes will likely be an essential component of future registration trials in EoE on the basis of existing precedents in both ulcerative colitis and Crohn's disease, whereby co-primary endpoints of PROs and objective assessment of inflammation (endoscopy) have been mandated. Although multiple scoring systems have been used to assess dysphagia symptoms in EoE RCTs, most have not been validated in this disease. Two disease-specific, validated symptom scoring systems have recently been developed. The Dysphagia Symptom Questionnaire was developed from patient focus groups and primarily assesses frequency and intensity of dysphagia symptoms, with demonstrated responsiveness in an RCT of budesonide oral suspension. 36 The EEsAI was prospectively developed and validated for use in adults with EoE and also captures food avoidance and behavioral modifications, 53 a common source of reduced quality of life in EoE patients, particularly among those with previous food bolus impactions. Although eating behaviors such as careful mastication, prolonged meal times, and dietary restriction may not be adequately captured by assessment of dysphagia symptoms alone, both indices are candidate measurement tools for evaluating PROs in future RCTs.
Endoscopic outcomes offer another potential objective treatment target in EoE RCTs. Earlier studies used non-validated global assessments of endoscopic appearance based on common EoE features. Development of the EREFS, which incorporates both major (fixed rings, exudates, furrows, edema, stricture) and minor features (crepe paper esophagus), has been an important advance. 54 The items for the EREFS were identified through a literature review, and a grading scheme was developed through consensus expert opinion. Internal validation, which is based on evaluation of a sampling of videos by 21 endoscopists with diverse experience and practice patterns, demonstrated moderate to good interobserver reliability. The EREFS is the proposed endoscopic endpoint in 4 registered RCTs, but it still requires further external validation, particularly evaluating the role of central blinded endoscopy reading and comparison of video versus still-image endoscopic assessment on reliability performance characteristics. 55 Although histologic, endoscopic, and symptom-based outcomes have traditionally been used to assess EoE activity, there has been growing interest in quantifying and targeting esophageal distensibility as a measure of end organ remodeling. Functional lumen imaging probe (FLIP) uses impedance planimetry to quantify esophageal distention. 6 Lower distensibility plateaus (DPs) are associated with food bolus impaction and the need for esophageal dilation. 45 In contrast, dietary and medical therapies have been demonstrated to improve DPs, and this reduction correlates with better symptomatic outcomes. 56 In a recent phase 2 placebo-controlled RCT, treatment with dupilumab, a humanized anti-IL4Ra monoclonal antibody, improved esophageal distensibility and highlighted the potential of FLIP as a responsive biomarker to medical therapy. 38 Understanding outcome definitions in clinical trials is crucial for translating evidence-based research to clinical practice. Indeed, many of the newer EoE disease activity indices such as the EoE-HSS, EEsAI, and EREFS have not yet been routinely incorporated in daily care. It is important for physicians to recognize that heterogeneity in outcome definitions used in clinical trials may influence interpretations of response to therapy. Because the patient's treatment goals are typically resolution of dysphagia symptoms, avoidance of food bolus impactions, prevention of long-term disease complications, and ultimately, optimization of quality of life, these are parameters that should be captured in outcome definitions for use in RCTs. In addition, choosing appropriate histologic and endoscopic targets will help dictate therapeutic decisions in clinical practice; for example, targeting more stringent histologic endpoints (<5 eosinophils/HPF vs <15 eosinophils/HPF) 57 or endoscopic resolution 58 is associated with improved treatment response and symptom alleviation.
Our study has some limitations. First, we included only placebo-controlled RCTs, and a substantial proportion of the EoE literature is rooted in observational studies and non-controlled trials. Thus, there may be outcomes of interest that are not captured in this review. Second, we excluded trials of endoscopic therapies or dietary interventions. We restricted the inclusion specifically to RCTs investigating pharmacologic therapies because the focus of COS development will be primarily applicable to RCTs of novel therapeutic compounds. However, similar symptom-based and histologic outcomes are measured in both prospective and retrospective observational studies of dietary interventions in EoE, with heterogeneity in the defined thresholds for response and remission remaining an important challenge. [59] [60] [61] [62] [63] A previous systematic review has also evaluated outcomes after endoscopic dilation for EoE 64 ; efficacy was typically assessed by using dysphagia scoring systems, although there is an increased focus on safety outcomes, particularly with respect to esophageal perforation. Finally, we could not pool placebo rates to generate single point estimates. However, it is considered methodologically inappropriate to pool studies with such heterogeneity in outcome definitions, leading to a potentially biased point estimate that is not representative of the literature. Thus, we have presented the median as a measure of central tendency with ranges rather than a pooled point estimate.
The next steps in COS development have been outlined in the Core Outcome Measures in Effectiveness Trials handbook. 65 First, input from relevant stakeholders, including patients, health care providers, trialists, regulators, industry representatives, health policy makers, and researchers, will be sought. Next, relevant outcome domains will be defined. We propose that a similar framework to that presented in this review be considered, wherein a co-primary endpoint incorporating a PRO measure and an objective histologic or endoscopic outcome in accordance with regulatory requirements be adopted. A consensus on specific outcome definitions and thresholds will be achieved through a multi-round Delphi process that permits anonymized feedback to participants. Finally, the COS will be ratified and disseminated for implementation in future RCTs.
Conclusion
Choosing appropriate treatment endpoints is crucial for clinical trial design. Outcomes should be relevant and valid, support regulatory and labelling claims, and correlate with meaningful changes in quality of life and disease course. In EoE, this translates to improvements in patient-reported symptoms, histologic burden of inflammation, and possibly reversal or prevention of fibrostenotic EoE complications. Although there has been significant progress in clinical trial research in EoE during the past 2 decades, we identify substantial heterogeneity in outcome definitions in this field. Many instruments for EoE outcome assessment have only recently been developed, and additional RCT data applying these instruments are required to adequately define response and remission cutoffs using anchor-based methods. This systematic review serves as a conceptual framework for COS development in EoE.
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